Results 111 to 120 of about 9,514 (200)

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents. [PDF]

Blood Cancer Discov
Drekolias D, Tuz Zahra F, Fileni C, Sallman DA, Mo Q, Chan O, Zhang L, Vincelette ND, Yu X, Sammut R, Moon J, Park J, Umasangtongkul SA, Lledo FM, Razabdouski TN, Cheng CH, Qin D, Mai K, Ball S, Shallis RM, Xie Z, Kuykendall AT, Padron E, Sweet K, Walker AR, Komrokji RS, Lancet JE, Niyongere S, Cluzeau T, Yun S.   +29 more
europepmc   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. [PDF]

Br J Haematol
Hoff FW, Trikha R, Groarke EM, Patel BA.
europepmc   +1 more source

Novel approaches to the use of hypomethylating agents in myeloid malignancies. [PDF]

Epigenomics
Cheng J, O'Connell C, O'Connell C.
europepmc   +1 more source

Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches. [PDF]

Clin Hematol Int
Cortiana V, Vallabhaneni H, Ghazal J, Itodo K, Kassim Dohadwala T, Park C, Leyfman Y.   +6 more
europepmc   +1 more source

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors. [PDF]

Ann Hematol
Jovein MM, Meyer T, Waterhouse M, Pfeifer D, Duque-Afonso J, Lübbert M, Maas-Bauer K, Wäsch R, Bertz H, Duyster J, Zeiser R, Finke J, Wehr C.   +12 more
europepmc   +1 more source

News on hypomethylating agents: Chasing the FOX [PDF]

Cell Cycle, 2011
openaire   +1 more source

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? [PDF]

Ann Hematol
Tarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F.   +30 more
europepmc   +1 more source

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. [PDF]

Hemasphere
Vänttinen I, Saad J, Ruokoranta T, Kytölä S, Qin G, Tercan B, Ettala P, Partanen A, Pyörälä M, Rimpiläinen J, Siitonen T, Manninen M, Valk PJM, Huls G, Thorsson V, Heckman CA, Kontro M, Kuusanmäki H.   +17 more
europepmc   +1 more source

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents. [PDF]

Ther Adv Hematol
Zeidan AM, Zhao R, Tepsick JG, Lan Z, Salimi T.   +4 more
europepmc   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]

Eur J Haematol
Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C, Mendicino F, Lucia E, Olivito V, Amodio N, Morabito F, Gentile M.   +11 more
europepmc   +1 more source